Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management
Primary sclerosing cholangitis is a chronic immune-mediated liver disease. Though rare, it poses several clinical concerns for the managing physician. There are currently limited therapeutic options in the management of the condition and weak evidence base behind them. Endoscopic intervention is lim...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-09-01
|
| Series: | Clinical Medicine Insights: Gastroenterology |
| Online Access: | https://doi.org/10.4137/CGast.S38451 |
| _version_ | 1819087385113133056 |
|---|---|
| author | Aditi Kumar Daniel Wheatley Amar Puttanna |
| author_facet | Aditi Kumar Daniel Wheatley Amar Puttanna |
| author_sort | Aditi Kumar |
| collection | DOAJ |
| description | Primary sclerosing cholangitis is a chronic immune-mediated liver disease. Though rare, it poses several clinical concerns for the managing physician. There are currently limited therapeutic options in the management of the condition and weak evidence base behind them. Endoscopic intervention is limited to those patients with obstructing stricture-related disease, and even liver transplantation has a risk of disease recurrence. Surveillance for inflammatory bowel disorders, metabolic bone disease, and malignancy is paramount when managing such patients. This article provides an overview of the condition with further focus on current therapeutic options and guidance on surveillance management. |
| first_indexed | 2024-12-21T21:35:18Z |
| format | Article |
| id | doaj.art-4a1e9b6416034c02a614836257817f9c |
| institution | Directory Open Access Journal |
| issn | 1179-5522 |
| language | English |
| last_indexed | 2024-12-21T21:35:18Z |
| publishDate | 2016-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Gastroenterology |
| spelling | doaj.art-4a1e9b6416034c02a614836257817f9c2022-12-21T18:49:31ZengSAGE PublishingClinical Medicine Insights: Gastroenterology1179-55222016-09-01910.4137/CGast.S38451Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance ManagementAditi Kumar0Daniel Wheatley1Amar Puttanna2Russells Hall Hospital, Dudley, UK.Russells Hall Hospital, Dudley, UK.University Hospital North Midlands, Stoke-on-Trent, England, UK.Primary sclerosing cholangitis is a chronic immune-mediated liver disease. Though rare, it poses several clinical concerns for the managing physician. There are currently limited therapeutic options in the management of the condition and weak evidence base behind them. Endoscopic intervention is limited to those patients with obstructing stricture-related disease, and even liver transplantation has a risk of disease recurrence. Surveillance for inflammatory bowel disorders, metabolic bone disease, and malignancy is paramount when managing such patients. This article provides an overview of the condition with further focus on current therapeutic options and guidance on surveillance management.https://doi.org/10.4137/CGast.S38451 |
| spellingShingle | Aditi Kumar Daniel Wheatley Amar Puttanna Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management Clinical Medicine Insights: Gastroenterology |
| title | Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management |
| title_full | Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management |
| title_fullStr | Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management |
| title_full_unstemmed | Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management |
| title_short | Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management |
| title_sort | primary sclerosing cholangitis therapeutic options and surveillance management |
| url | https://doi.org/10.4137/CGast.S38451 |
| work_keys_str_mv | AT aditikumar primarysclerosingcholangitistherapeuticoptionsandsurveillancemanagement AT danielwheatley primarysclerosingcholangitistherapeuticoptionsandsurveillancemanagement AT amarputtanna primarysclerosingcholangitistherapeuticoptionsandsurveillancemanagement |